Inspira™ Approached by Large Medical Company to Evaluate Operation of their Key Product with INSPIRA™ ART100 - Results Exceed 100% at Maximum Flow
Inspira Technologies (Nasdaq: IINN) has announced that a leading medical technology company approached them to evaluate the operation of their key product in combination with the INSPIRA™ ART100 system. The evaluation, conducted by Inspira researchers, showed that test results exceeded 100% of the standard value for gas transfer at maximum flow when integrated with the ART100 system.
The tests were performed in Inspira's advanced laboratory, simulating oxygen-deficient and carbon dioxide-rich blood conditions. The successful results demonstrate the power and versatility of the INSPIRA™ ART100 system in various technology settings. Inspira believes this validates the system's compatibility and performance with key products of a leading medical technology company, potentially leading to meaningful business development activities.
Inspira Technologies (Nasdaq: IINN) ha annunciato che una delle principali aziende di tecnologia medica si è rivolta a loro per valutare il funzionamento del loro prodotto chiave in combinazione con il sistema INSPIRA™ ART100. La valutazione, condotta dai ricercatori di Inspira, ha mostrato che i risultati dei test hanno superato il 100% del valore standard per il trasferimento di gas al flusso massimo quando integrati con il sistema ART100.
I test sono stati effettuati nel laboratorio avanzato di Inspira, simulando condizioni di sangue povero di ossigeno e ricco di anidride carbonica. I risultati positivi dimostrano la potenza e versatilità del sistema INSPIRA™ ART100 in vari contesti tecnologici. Inspira crede che questo convalida la compatibilità e le prestazioni del sistema con i prodotti chiave di una grande azienda di tecnologia medica, potenzialmente portando a significative attività di sviluppo commerciale.
Inspira Technologies (Nasdaq: IINN) ha anunciado que una importante empresa de tecnologías médicas se acercó a ellos para evaluar el funcionamiento de su producto clave en combinación con el sistema INSPIRA™ ART100. La evaluación, realizada por investigadores de Inspira, mostró que los resultados de las pruebas superaron el 100% del valor estándar para la transferencia de gas a flujo máximo cuando se integraron con el sistema ART100.
Las pruebas se llevaron a cabo en el laboratorio avanzado de Inspira, simulando condiciones de sangre con bajos niveles de oxígeno y altos niveles de dióxido de carbono. Los resultados exitosos demuestran la potencia y versatilidad del sistema INSPIRA™ ART100 en diversos entornos tecnológicos. Inspira cree que esto valida la compatibilidad y el rendimiento del sistema con productos clave de una importante empresa de tecnología médica, lo que podría llevar a significativas actividades de desarrollo comercial.
인스피라 테크놀로지스(Nasdaq: IINN)는 주요 의료 기술 회사가 그들의 주요 제품과 INSPIRA™ ART100 시스템의 조합을 평가하기 위해 접근해 왔다고 발표했습니다. 인스피라 연구원의 평가 결과, 테스트 결과 최대 유량에서 가스 전송에 대한 표준 값을 100% 초과했다고 합니다. 이는 ART100 시스템과 통합되었을 때 나타났습니다.
테스트는 인스피라의 첨단 연구실에서 산소 결핍 및 이산화탄소가 풍부한 혈액 조건을 시뮬레이션하여 수행되었습니다. 성공적인 결과는 INSPIRA™ ART100 시스템의 강력함과 다재다능함을 다양한 기술 환경에서 입증합니다. 인스피라는 이것이 시스템의 호환성과 성능을 주요 의료 기술 회사의 핵심 제품과 함께 검증한다 믿으며, 의미 있는 사업 개발 활동으로 이어질 수 있다고 예상합니다.
Inspira Technologies (Nasdaq: IINN) a annoncé qu'une entreprise leader dans le domaine de la technologie médicale les a contactés pour évaluer le fonctionnement de leur produit clé en combinaison avec le système INSPIRA™ ART100. L'évaluation, réalisée par les chercheurs d'Inspira, a montré que les résultats des tests ont dépassé 100 % de la valeur standard pour le transfert de gaz à débit maximum lorsqu'ils étaient intégrés au système ART100.
Les tests ont été effectués dans le laboratoire avancé d'Inspira, simulant des conditions de sang appauvri en oxygène et riche en dioxyde de carbone. Les résultats positifs démontrent la puissance et la polyvalence du système INSPIRA™ ART100 dans divers environnements technologiques. Inspira estime que cela valide la compatibilité et les performances du système avec les produits clés d'une entreprise leader en technologie médicale, ce qui pourrait conduire à des activités de développement commercial significatives.
Inspira Technologies (Nasdaq: IINN) hat angekündigt, dass ein führendes Unternehmen der Medizintechnologie sich mit der Bitte um Evaluierung des Betriebs ihres Hauptprodukts in Kombination mit dem INSPIRA™ ART100-System an sie gewandt hat. Die Bewertung, die von Inspira-Forschern durchgeführt wurde, zeigte, dass die Testergebnisse 100% des Standardwerts für den Gastransfer bei maximalem Durchfluss übertrafen, als sie mit dem ART100-System integriert wurden.
Die Tests wurden im fortschrittlichen Labor von Inspira durchgeführt, wobei Bedingungen von sauerstoffarmem und kohlendioxidhaltigem Blut simuliert wurden. Die positiven Ergebnisse zeigen die Leistungsfähigkeit und Vielseitigkeit des INSPIRA™ ART100-Systems in verschiedenen technischen Umgebungen. Inspira ist der Ansicht, dass dies die Kompatibilität und Leistung des Systems mit den Schlüsselprodukten eines führenden Medizintechnikunternehmens validiert und potenziell zu bedeutenden Geschäftsentwicklungsaktivitäten führen könnte.
- Test results exceeded 100% of standard value for gas transfer at maximum flow
- Successful evaluation validates INSPIRA™ ART100 system's compatibility with key products of a leading medical technology company
- Potential for meaningful business development activities with industry players
- None.
The successful evaluation of a leading medical company's key product with the INSPIRA™ ART100 system is a significant development for Inspira Technologies. The test results, exceeding 100% of standard gas transfer value at maximum flow, demonstrate the system's exceptional performance and compatibility. This achievement could potentially open new doors for collaborations and expand the application scope of the INSPIRA™ ART100.
However, it's important to note that this is an early-stage evaluation. The path to commercialization and widespread adoption in clinical settings may still be long and complex. Investors should monitor for follow-up studies, regulatory approvals and concrete partnership agreements to gauge the long-term impact on Inspira's market position and financial performance.
This development signals growing industry interest in Inspira's technology, potentially strengthening the company's market position. The successful evaluation by a leading medical technology company could enhance Inspira's credibility and attract attention from other industry players. This might lead to new partnership opportunities or licensing agreements, potentially accelerating market penetration.
However, investors should remain cautious. The medical device market is highly competitive and successful lab tests don't guarantee commercial success. It's important to monitor how this translates into concrete business agreements, revenue growth and market share gains in the coming quarters. The company's ability to scale production and navigate regulatory hurdles will be key factors in capitalizing on this positive development.
RA'ANANA,
The evaluation tests were conducted in Inspira's advanced laboratory, adhering to rigorous regulatory guidelines. The process involved a setting that enabled continuous, real-time management of blood parameters across various blood flow rates, simulating oxygen-deficient and carbon dioxide-rich blood post-circulation through body organs and tissues. This series of evaluations confirmed that the integrated system met the specified requirements, performing to expectations without any technical malfunctions or abnormal effects on the blood.
We believe that the successful test results are a clear indication of the power and versatility of the INSPIRA™ ART100 system when used in various settings of technologies. The INSPIRA™ ART100 system's unique design and advanced capabilities provide a comprehensive platform of efficiency, compatibility and performance, enabling medical technologies companies to refine and optimize the products for improved patient care.
Dagi Ben-Noon, CEO of Inspira Technologies, stated, "We believe that this successful evaluation validates the INSPIRA™ ART100 system's compatibility and performance with key products of a leading medical technology company. I believe that this further indicates that industry players are acknowledging our growing capabilities and that we have the potential to translate these capabilities into meaningful business development activities."
Inspira Technologies OXY B.H.N. Ltd.
Inspira™ Technologies targets to reshape the respiratory and life-support landscape. We are developing novel expanding life support technologies with Inspira blood oxygenation and blood monitoring technologies. Inspira is on a quest to become the leading ground-breaking medical device company in our field with business alliances around the world.
The INSPIRA™ ART (Gen 2), also known as the INSPIRA™ ART500, will include the Company's Adaptive Blood Oxygenation technology and is being designed to continuously measure the patient's blood parameters in real-time, delivering needed oxygen volume straight into the blood. By elevating patient oxygen saturation levels in minutes, this technology potentially allows patients to remain awake during treatment and therefore may enable patients to be treated in and beyond intensive care units, reducing the need for mechanical ventilation systems that require intubation and medically induced coma.
The Company's INSPIRA™ ART100 system received FDA 510(k) clearance for Cardiopulmonary Bypass procedures and AMAR certification for Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures.
The Company's other products, including the INSPIRA™ ART (Gen 2) including the INSPIRA Cardi-ART portable modular device and HYLA™ blood sensor are currently being designed and developed, and have not yet been tested or used in humans and have not been approved by any regulatory entity.
For more information, please visit our corporate website: https://inspira-technologies.com.
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to
Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD. All rights reserved.
For more details:
Adi Shmueli
Public Relations Manager
Inspira Technologies
info@inspirao2.com
+972-9-9664485
Logo: https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/inspira-approached-by-large-medical-company-to-evaluate-operation-of-their-key-product-with-inspira-art100--results-exceed-100-at-maximum-flow-302221019.html
SOURCE Inspira Technologies
FAQ
What were the results of the INSPIRA™ ART100 system evaluation?
How does the INSPIRA™ ART100 system perform in various technology settings?
What potential business opportunities does this evaluation create for Inspira Technologies (IINN)?
